{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Podcast","title":"New Approaches: Marstacimab Therapy and HLH Biomarkers","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/18f11dc5\"></iframe>","width":"100%","height":180,"duration":1070,"description":"In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood.  Dr. Mahlangu discusses study details and next steps from \"Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial\" which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind \"CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis\", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.","thumbnail_url":"https://img.transistorcdn.com/v7MGyoJEM-ebFBYi5VpSwDRF3QY3zbinfCyyOAH1TGk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kY2Q4/YzJhZmMwODBjOWRi/YTNhN2Y1NWJkMzMw/NTBjZi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}